跳至主要内容
临床试验/NCT00626834
NCT00626834
已完成
1 期

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study

National Institute on Drug Abuse (NIDA)1 个研究点 分布在 1 个国家目标入组 24 人2008年2月

概览

阶段
1 期
干预措施
Vigabatrin
疾病 / 适应症
Cocaine Addiction
发起方
National Institute on Drug Abuse (NIDA)
入组人数
24
试验地点
1
主要终点
safety/tolerability and AE assessments including HR/BP/ECG/QTc
状态
已完成
最后更新
9年前

概览

简要总结

This is a Phase 1 safety/tolerably study to determine if there are clinically significant interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent with intravenous (IV) cocaine infusions.

详细描述

STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of the effects of VGB compared to placebo control on the physiological and subjective effects of IV infusions of cocaine (cocaine experienced volunteers). Subjects will be randomized within each clinical site to one of four groups (placebo control or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will receive double-blind infusions of saline and cocaine. Subjects will be asked to return for follow-up approximately 7 and 14 days after the day of clinic discharge. STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments and investigational products administration, and two follow-up visits after clinic discharge. SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or placebo. POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45 years of age.

注册库
clinicaltrials.gov
开始日期
2008年2月
结束日期
2010年10月
最后更新
9年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

入排标准

入选标准

  • Be between 18 and 45 years of age, inclusive
  • Currently be a non-treatment seeking cocaine user as confirmed by a positive urine test for cocaine
  • Able to provide written informed consent
  • A negative pregnancy test within 72 hours prior to receiving the first infusion of cocaine

排除标准

  • Please contact site for more information.

研究组 & 干预措施

Vigabatrin Dose 1

干预措施: Vigabatrin

Vigabatrin Dose 2

干预措施: Vigabatrin

Vigabatrin Dose 3

干预措施: Vigabatrin

Matching placebo

干预措施: Matching placebo

结局指标

主要结局

safety/tolerability and AE assessments including HR/BP/ECG/QTc

时间窗: 56 days

次要结局

  • VGB/PK during cocaine infusions and effect of VGB on cocaine craving(28 days)

研究点 (1)

Loading locations...

相似试验